Your browser doesn't support javascript.
loading
Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study.
Granja López, Juan; Estebas Armas, Carlos; Lorenzo Dieguez, Manuel; Puertas Muñoz, Inmaculada; De Celis Ruiz, Elena; Rigual, Ricardo; Fernández-Fournier, Mireya; Torres Iglesias, Gabriel; Sánchez Velasco, Sara; Tallón Barranco, Antonio; Rogozina, Olga; Ramírez, Elena; González-Muñoz, Miguel; Lacruz Ballester, Laura.
Affiliation
  • Granja López J; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Estebas Armas C; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Lorenzo Dieguez M; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Puertas Muñoz I; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • De Celis Ruiz E; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Rigual R; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Fernández-Fournier M; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Torres Iglesias G; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Sánchez Velasco S; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Tallón Barranco A; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
  • Rogozina O; Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • Ramírez E; Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • González-Muñoz M; Immunology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain.
  • Lacruz Ballester L; Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autónoma de Madrid), Madrid, Spain.
Front Pharmacol ; 15: 1376474, 2024.
Article in En | MEDLINE | ID: mdl-39175548
ABSTRACT

Objectives:

To know the frequency and characteristics of neurological manifestations of probable immune origin occurring after exposure to COVID-19 vaccination. In addition, to pre-study the usefulness of the Spanish pharmacovigilance system and lymphocyte transformation test in establishing causality.

Methods:

Retrospective case study, including patients admitted to the Neurology department from January 2021 to May 2022 with a probable neuroimmune disorder. Demographic, clinical and COVID-19 vaccination antecedent data were collected from medical records.

Results:

From a total of 108 patients, 30 were excluded due to a different etiological diagnosis after follow-up. Thirty-six patients (46.2%) had received the COVID-19 vaccine in the previous 3 months (21.8% during the previous month). BioNTech-Pfizer vaccine was the most frequent in this group (63.9%). 69/108 were female and mean age 51.2 years (SD 22.59), with no significant difference with not recently-vaccinated (U-Mann Whitney, p = 0.256). The neurological syndromes found were (vaccinated/total) polyradiculoneuropathy (8/16), encephalitis (5/11), multiple sclerosis relapse (5/16), optic neuritis (1/4), myelitis (3/6), cranial neuropathy (6/10), aseptic meningitis (1/3) and others (7/11). Acute immunosuppressive treatment was administered in 61.1% of cases and 47.2% presented complete clinical improvement, without significant differences with non-vaccinated patients (chi-square, p = 0.570). Eleven vaccinated patients were studied in the pharmacovigilance office for possible adverse drug reaction. Causality according to the Spanish pharmacovigilance system (SPVS) algorithm was "Related" to COVID-19 vaccine (score ≥ 4) in 11 cases with positive in vitro study (lymphocyte transformation test) to polyethylene glycol-2000 and polysorbate-80 in 4 cases.

Conclusion:

Neuroimmune disorders appearing after administration of COVID-19 vaccine do not seem to present important differentiating clinical and/or evolutive features. Delayed hypersensitivity to vaccine excipients could be one of the pathophysiological mechanisms, and lymphocyte transformation test is a useful tool to identify it.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article Affiliation country: España Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article Affiliation country: España Country of publication: Suiza